Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 237-243 , 1 March 2010

Nicotine patch vs. nicotine lozenge for smoking cessation: An effectiveness trial coordinated by the Community Clinical Oncology Program

  • Robert A. Schnoll

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, 3535 Market Street, 4th Floor, Philadelphia, PA 19104, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 215 746 7143; fax: +1 215 746 7140.
    • ,
  • Elisa Martinez

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, 3535 Market Street, 4th Floor, Philadelphia, PA 19104, United States
    • ,
  • Kristina L. Tatum

      Affiliations

    • Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States
    • ,
  • Marcella Glass

      Affiliations

    • Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States
    • ,
  • Albert Bernath

      Affiliations

    • Geisinger Medical Center, 100 North Academy Road, Danville, PA 17822, United States
    • ,
  • Daron Ferris

      Affiliations

    • Department of Family Medicine and Obstetrics and Gynecology, Medical College of Georgia, 1120 15th St, HH-105, Augusta, GA 30912, United States
    • ,
  • Patrick Reynolds

      Affiliations

    • Mt. Sinai Medical Center, 4306 Alton Road, Mt. Sinai CCC, Miami Beach, FL 33140, United States

Received 27 August 2009 ,Revised 2 November 2009 ,Accepted 6 November 2009.

References 

  1. Alterman AI, Gariti P, Cook TG, Cnaan A. Nicodermal patch adherence and its correlates. Drug Alcohol. Depend. 1999;53:159–165
  2. Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob. Control. 2009;18:34–42
  3. Benowitz NL, Jacob P, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J. Biochemical verification of tobacco use and cessation. Nicotine Tob. Res. 2002;4:149–159
  4. Brown RA, Burgess ES, Sales SD, Whiteley JA, Evans DM, Miller IW. Reliability and validity of a smoking timeline follow-back interview. Psychol. Addict. Behav. 1998;12:101–112
  5. Evans DE, Drobes DJ. Nicotine self-medication of cognitive-attentional processing. Addict. Biol. 2009;14:32–42
  6. Fagerström KO, Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?. Tob. Control. 1997;6:311–316
  7. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008;
  8. Gehricke JG, Loughlin SE, Whalen CK, Potkin SG, Fallon JH, Jamner LD, et al. Smoking to self-medicate attentional and emotional dysfunctions. Nicotine Tob. Res. 2007;9:S523–S536
  9. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55
  10. Hasford J, Fagerstrom KO, Haustein KO. A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur. J. Clin. Pharmacol. 2003;59:443–447
  11. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991;86:1119–1127
  12. Horn D, Waingrow S. Some dimensions of a model for smoking behavior change. Am. J. Public Health. 1966;56:21–56
  13. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. 2003;5:13–25
  14. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob. Control. 2003;12:12–27
  15. Jonk YC, Sherman SE, Fu SS, Hamlett-Berry KW, Geraci MC, Joseph AM. National trends in the provision of smoking cessation aids within the Veterans Health Administration. Am. J. Manage. Care. 2005;11:77–85
  16. Jorenby DE, Hays JT, Rigotti NA, Rigotti NA, Azoulay S, Watsky EJ. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63
  17. Leischow SJ, Valente SN, Hill AL, Otte PS, Aickin M, Holden T, et al. Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp. Clin. Psychopharmacol. 1997;5:54–64
  18. Lerman C, Audrain J, Orleans CT, Boyd R, Gold K, Main D, et al. Investigation of mechanisms linking depressed mood to nicotine dependence. Addict. Behav. 1996;21:9–19
  19. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol. 1998;17:56–62
  20. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann. Intern. Med. 2004;140:426–433
  21. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288:1260–1264
  22. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weille E, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59:22–33
  23. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction. 2007;102:809–814
  24. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch. Intern. Med. 2002;162:1267–1276
  25. Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang YK, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002;97:505–516
  26. Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacol. (Berl.). 2003;166:343–350
  27. Stead L, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2008;21:CD000146
  28. Velicer WF, Diclemente CC, Rossi JS, Prochaska JO. Relapse situations and self-efficacy: an integrative model. Addict. Behav. 1990;15:271–283
  29. Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Cue-provoked craving and nicotine replacement therapy in smoking cessation. J. Consult. Clin. Psychol. 2004;72:1136–1143
  30. West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacol. (Berl.). 2001;153:225–230

PII: S0376-8716(09)00408-6

doi: 10.1016/j.drugalcdep.2009.11.001

Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 237-243 , 1 March 2010

Article Tools

* Image Usage & Resolution